Goldman Reiterates Buy on Edwards Lifesciences (EW)
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $91.60 -1.04%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs reiterated their Buy rating on Edwards Lifesciences (NYSE: EW). They have a 12-month price target of $118.00 on the stock.
Analyst David Roman said "The first two full quarters of the US THV launch provide an early indication of the potential for this technology. In addition, our conversations with management suggest that there is abundant patient,
hospital, and physician demand for THV. Management has actually
governed the launch to ensure appropriate training, as the company is highly focused on obtaining strong procedural success rates."
"Beyond the US THV launch, the company has a fairly extensive pipeline that should further build a moat around global share. Importantly, Edwards should have a second generation product on the US market before Medtronic enters in late CY2014. Lastly, we see the company’s P&L having significant upside, as our EPS estimates for 2013E and 2014E are 6% and 14% above consensus, respectively," added Roman.
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $101.32 yesterday.
Analyst David Roman said "The first two full quarters of the US THV launch provide an early indication of the potential for this technology. In addition, our conversations with management suggest that there is abundant patient,
hospital, and physician demand for THV. Management has actually
governed the launch to ensure appropriate training, as the company is highly focused on obtaining strong procedural success rates."
"Beyond the US THV launch, the company has a fairly extensive pipeline that should further build a moat around global share. Importantly, Edwards should have a second generation product on the US market before Medtronic enters in late CY2014. Lastly, we see the company’s P&L having significant upside, as our EPS estimates for 2013E and 2014E are 6% and 14% above consensus, respectively," added Roman.
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $101.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- McGraw Hill (MH) PT Raised to $15 at UBS
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
